A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

被引：0
|
作者：
Fuchs, C. [1 ]
Shahidi, J. [2 ]
Mathew, L. [2 ]
Qin, A. [2 ]
Van Cutsem, E. [3 ,4 ]
机构：
[1] Yale Canc Ctr, Smilow Canc Hosp, New Haven, CT USA
[2] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[3] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium
[4] Katholieke Univ Leuven, Leuven, Belgium
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.266
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-184
引用
收藏
页码：S150 / S150
页数：1
相关论文
共 50 条
  • [31] Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
    Shitara, Kohei
    Iwata, Hiroji
    Takahashi, Shunji
    Tamura, Kenji
    Park, Haeseong
    Modi, Shanu
    Tsurutani, Junji
    Kadowaki, Shigenon
    Yamaguchi, Kensei
    Iwasa, Satoru
    Saito, Kaku
    Fujisaki, Yoshihiko
    Sugihara, Masahiro
    Shahidi, Javad
    Doi, Toshihiko
    LANCET ONCOLOGY, 2019, 20 (06): : 827 - 836
  • [32] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
    Yoshino, Takayuki
    Di Bartolomeo, Maria
    Raghav, Kanwal Pratap Singh
    Masuishi, Toshiki
    Loupakis, Fotios
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Wainberg, Zev A.
    Elez, Elena
    Rodriguez, Javier
    Fakih, Marwan
    Ciardiello, Fortunato
    Saxena, Kapil
    Kobayashi, Kojiro
    Bako, Emarjola
    Okuda, Yasuyuki
    Meinhardt, Gerold
    Grothey, Axel
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
    Tarantino, P.
    Tolaney, S. M.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 949 - 950
  • [34] Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
    Saura Manich, C.
    Modi, S.
    Krop, I.
    Park, Y. H.
    Kim, S-B.
    Tamura, K.
    Andre, F.
    Iwata, H.
    Ito, Y.
    Tsurutani, J.
    Sohn, J.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Singh, J.
    Yamashita, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S485 - S486
  • [35] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Nie, Tina
    Blair, Hannah A.
    TARGETED ONCOLOGY, 2023, 18 (03) : 463 - 470
  • [36] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Tina Nie
    Hannah A. Blair
    Targeted Oncology, 2023, 18 : 463 - 470
  • [37] Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+advanced gastric or gastroesophageal junction adenocarcinoma
    Shitara, Kohei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-Hee
    Sakai, Daisuke
    Chung, Hyun Cheol Cheol
    Omuro, Yasushi
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Sakamoto, Yasuhiro
    Nishina, Tomohiro
    Inaki, Koichiro
    Kuwahara, Yusuke
    Suto, Fumitaka
    Sugihara, Masahiro
    Saito, Kaku
    Kojima, Akihito
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [38] Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study.
    Borghaei, Hossein
    Besse, Benjamin
    Bardia, Aditya
    Mazieres, Julien
    Popat, Sanjay
    Augustine, Bincy
    D'amelio, Anthony Michael
    Barrios, Daniel
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-gastric04, DG-04): A randomized phase III study
    Shitara, K.
    Seraj, J.
    Franke, F. A.
    Kawaguchi, Y.
    Shen, L.
    Kamio, T.
    Meinhardt, G.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1073 - S1073
  • [40] A phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)
    Zaman, K.
    Modi, S.
    Ohtan, S.
    Lee, C.
    Wang, Y.
    Saxena, K.
    Cameron, D. A.
    SWISS MEDICAL WEEKLY, 2020, : 28S - 29S
12345